BRP (BRINP2-related peptide) is a naturally occurring 12-amino-acid peptide identified by Stanford researchers in 2025 using an AI-driven prohormone-cleavage prediction tool. It suppresses appetite via the hypothalamic cAMP–PKA–CREB–FOS cascade — a pathway entirely distinct from the GLP-1 receptor. Because BRP does not engage the area postrema, it produces equivalent food-intake reduction without triggering nausea or conditioned taste aversion.
How Was BRP Discovered, and What Is Its Structural Identity?
BRP is a 12-mer peptide cleaved from the BRINP2 precursor protein. Stanford researchers identified it in 2025 using Peptide Predictor, an AI tool that scans the proteome for prohormone cleavage sites. The discovery was published in Nature (Coassolo et al., 2025; PMID 40044869), establishing BRP as a naturally occurring signalling molecule rather than a synthetic construct.
BRINP2 is a brain-enriched protein whose endogenous peptide products had not previously been characterised as appetite regulators. The AI pipeline predicted that a specific 12-amino-acid fragment would be released by prohormone convertase cleavage under physiological conditions. Subsequent mass spectrometry confirmed the peptide's endogenous presence in brain tissue.
The 12-mer structure is notably compact relative to most therapeutic peptides. Its small size raises the possibility of oral bioavailability optimisation, though no pharmacokinetic data in humans have been published as of mid-2026. The preclinical pharmacology was characterised in both mouse and pig models, providing cross-species validation of the core anorexigenic signal.
What Is BRP's Mechanism of Appetite Suppression in the Hypothalamus?
BRP acts on hypothalamic neurons by elevating intracellular cyclic AMP (cAMP), activating protein kinase A (PKA), which phosphorylates CREB and induces FOS expression. This cAMP–PKA–CREB–FOS cascade is mechanistically independent of the GLP-1 receptor pathway and concentrates BRP's anorexigenic signal within hypothalamic energy-balance circuits rather than across the distributed receptor network engaged by incretin drugs.
The hypothalamic specificity of BRP's action is a defining pharmacological feature. Unlike GLP-1 receptor agonists, which engage receptors distributed across the gut, pancreas, brainstem, and hypothalamus simultaneously, BRP's anorexigenic signal appears concentrated in hypothalamic circuits. This anatomical restriction is the primary mechanistic explanation for its absence of emetic side effects.
Dose-response data from the Coassolo et al. study showed that BRP at 5 mg/kg significantly reduced food intake relative to vehicle controls within one hour of administration. At 20 mg/kg, feeding was nearly completely suppressed over the same observation window. These effects were maintained in diet-induced obese mouse models, indicating that the hypothalamic target population does not undergo the same desensitisation seen with chronic high-fat feeding.
The FOS induction pattern localised predominantly to the arcuate nucleus and paraventricular nucleus — regions classically associated with satiety signalling via POMC and AgRP neuronal populations. Whether BRP directly modulates POMC or AgRP neurons, or acts on an upstream interneuron population, remains under active investigation as of 2026.
Why Does BRP Avoid the Nausea That GLP-1 Drugs Cause?
GLP-1 receptor agonists trigger nausea by activating receptors in the area postrema — the brainstem's emetic control centre. A 2025 RAND survey of nearly 9,000 GLP-1 users found approximately 50% reported nausea. BRP does not bind the GLP-1 receptor and shows no area postrema activity in preclinical studies, producing equivalent appetite suppression without engaging the emetic pathway.
The mechanistic divergence is stark. GLP-1 receptor agonists achieve appetite suppression partly through a central anorexigenic signal and partly through gastric emptying delay — both of which contribute to nausea at therapeutic doses. BRP's hypothalamic-restricted mechanism bypasses both the area postrema and the enteric nervous system, leaving gastric motility unaffected in preclinical data.
Researchers confirmed BRP's nausea-free profile using two standard preclinical assays. In the kaolin consumption test — a rodent proxy for nausea in which animals consume inert clay when nauseated — BRP-treated mice showed no increase in kaolin intake relative to controls. In conditioned taste aversion testing, BRP-treated animals did not develop aversion to a novel flavour paired with peptide administration, a response that GLP-1 agonists reliably produce at anorexigenic doses.
This dual negative result across both nausea assays is considered a high-confidence preclinical signal. Conditioned taste aversion is regarded as a sensitive and translatable measure of visceral malaise, making BRP's clean profile in this assay a meaningful differentiator from the incretin drug class.
What Do the Preclinical Efficacy Data Show for BRP in Obesity Models?
In diet-induced obese mice, daily BRP administration produced significant reductions in cumulative food intake and body weight gain. A single pre-meal injection reduced food intake by up to 50% within one hour. Cross-species validation in pigs confirmed the anorexigenic effect, strengthening the translational case beyond rodent-only data.
The obese mouse data are particularly relevant because GLP-1 receptor agonists show attenuated hypothalamic GLP-1 receptor expression in diet-induced obesity, which partly underlies the dose-escalation requirements seen clinically with semaglutide and liraglutide. BRP's maintained efficacy in the obese phenotype suggests its hypothalamic target population retains functional responsiveness under metabolic stress conditions.
No head-to-head dose-equivalence study comparing BRP directly to semaglutide or liraglutide at matched body-weight-reduction endpoints has been published as of mid-2026. The claim that BRP "matches GLP-1 efficacy" is a qualitative comparison based on food intake reduction magnitude in parallel experimental arms, not a controlled equivalence trial. This distinction is critical for interpreting the clinical relevance of current data.
What Does BRP's Non-Incretin Classification Mean Clinically?
BRP does not stimulate insulin secretion, does not modulate glucagon release, and does not engage any component of the incretin axis. This means BRP is unlikely to carry the hypoglycaemia risk associated with GLP-1 agonists in insulin-sensitised patients, and would not produce the pancreatic beta-cell effects that complicate incretin drug use in certain metabolic phenotypes.
The incretin axis — encompassing GLP-1, GIP, and their respective receptors — is deeply integrated with glucose homeostasis. Drugs targeting this axis inevitably produce metabolic effects beyond appetite suppression, including insulin secretion potentiation, glucagon suppression, and gastric emptying delay. BRP's mechanism is orthogonal to all of these, suggesting a fundamentally different risk-benefit profile requiring independent characterisation in human trials.
For practitioners managing patients with obesity and concurrent type 2 diabetes, the non-incretin classification raises an important question: would BRP provide additive appetite suppression when combined with existing GLP-1 therapy without compounding gastrointestinal side effects? The mechanistic case for additive efficacy is plausible, but no combination data exist as of 2026. This represents one of the most clinically relevant open questions in the BRP research programme.
What Is the Current Research-Stage Protocol Context for BRP?
As of mid-2026, BRP has no approved clinical protocol, no registered Phase 1 human trial, and no established human dosing regimen. All data derive from preclinical rodent and porcine studies. IND-enabling toxicology and human pharmacokinetics have not been published, and no clinical use is currently supported by the available evidence base.
| Parameter | Current Status | Evidence Source |
|---|---|---|
| Structure | 12-amino-acid peptide, BRINP2-derived | Coassolo et al., Nature, 2025 |
| Primary mechanism | Hypothalamic cAMP–PKA–CREB–FOS activation | Coassolo et al., Nature, 2025 |
| Receptor target | Unknown; not GLP-1R, not incretin axis | Coassolo et al., Nature, 2025 |
| Nausea profile (preclinical) | No kaolin consumption increase; no conditioned taste aversion | Coassolo et al., Nature, 2025 |
| Efficacy (mice) | Up to 50% food intake reduction at 20 mg/kg; maintained in DIO models | Coassolo et al., Nature, 2025 |
| Cross-species validation | Confirmed in pigs | Coassolo et al., Nature, 2025 |
| Human pharmacokinetics | Not published | — |
| Phase 1 trial status | Not registered as of mid-2026 | ClinicalTrials.gov search |
| Regulatory status | Research compound; no IND or approval | — |
What Are the Known and Anticipated Safety Considerations for BRP?
No human safety data for BRP exist as of mid-2026. Preclinical studies in mice and pigs reported no overt adverse effects at anorexigenic doses, and the absence of nausea-related behaviours is an encouraging early signal. However, the complete toxicology profile — including off-target binding, chronic exposure effects, immunogenicity, and organ-level safety — remains entirely uncharacterised.
Several safety questions are inherent to the compound's mechanism and origin. BRP is derived from BRINP2, a protein expressed in the developing and adult brain with roles in neuronal differentiation. The long-term consequences of pharmacologically elevating cAMP–PKA–CREB signalling in hypothalamic circuits — a pathway also involved in synaptic plasticity, stress response, and circadian regulation — have not been studied in chronic administration models.
The 12-amino-acid structure raises standard peptide-class safety considerations: proteolytic stability, immunogenicity potential, and off-target binding to structurally similar receptors. No stability or immunogenicity data have been published. Practitioners should note that the absence of reported adverse effects in short-duration preclinical studies does not constitute a safety clearance for human use.
Given the compound's brain-restricted expression pattern and central mechanism of action, any future clinical development will require careful neuropsychiatric monitoring. Appetite-regulating hypothalamic circuits are closely integrated with mood, reward, and stress-response systems, and unintended modulation of these networks is a recognised concern for centrally acting anorexigenic agents.
What Is the Clinical Development Outlook for BRP in 2026?
BRP's clinical development is at the earliest translational stage in 2026. The Stanford team has filed patent applications covering BRINP2-derived peptide compositions for obesity treatment, signalling commercial intent. The gap between preclinical proof-of-concept and a Phase 1 IND filing typically spans two to four years of enabling studies, and no human trial timeline has been publicly announced.
The compound's differentiation from GLP-1 agonists — particularly the nausea-free profile — gives it a clinically meaningful development rationale. Approximately 30–50% of patients discontinue GLP-1 therapy within the first year, with nausea and vomiting cited as leading reasons. A mechanistically distinct appetite suppressant without these side effects would address a genuine unmet clinical need in the obesity treatment landscape.
The non-incretin classification also opens a potential combination therapy pathway. If BRP's hypothalamic mechanism proves additive with GLP-1 receptor agonism at the level of appetite suppression — without compounding emetic signalling — it could be developed as an adjunct rather than a replacement. This may represent a more realistic near-term development path given the dominance of semaglutide and tirzepatide in the current obesity drug market.
For context on how GLP-1 receptor agonists are currently used in clinical practice, see the semaglutide cardiovascular evidence review on peptidetherapyindex.com. For the metabolic performance implications of GLP-1 therapy and lean mass considerations, see the GH peptides and GLP-1 lean mass analysis on peptidegenics.com. What Does 2026 Research Show About Tirzepatide's Clinical Efficacy and Safety in Metabolic Diseases Beyond Diabetes and Obesity? Can Growth Hormone Peptides Counter the 30% Lean Mass Loss Risk During GLP-1 Monotherapy in 2026? What Does 2026 Research Reveal About BPC-157's Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers?